Hyperlipidaemia and cardiovascular disease: Inflammation and oxidative stress in diabetic patients

Current Opinion in Lipidology

Volumn 20, Issue 3, 2009, Pages 258-259

  Aviram, Michael ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; POLYPHENOL DERIVATIVE; ROSUVASTATIN;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; CORONARY ARTERY OBSTRUCTION; DIABETIC PATIENT; EDITORIAL; ENDOTHELIUM INJURY; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INSULIN RESISTANCE; LIPID DEGRADATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; POMEGRANATE JUICE; PRIORITY JOURNAL; PROTEIN DEGRADATION; STROKE;

CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; FEMALE; HUMANS; HYPERLIPIDEMIAS; INFLAMMATION; MALE; OXIDATIVE STRESS;

EID: 67049099187     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32832b7167     Document Type: Editorial

References (8)

1. Dhimada K, Fujita M, Tanaka A, et al. Elevated serum C-reactive protein levels predict cardiovascular events in the Japanese coronary artery disease (JCAD) study. Circ J 2009; 73:78-85. In the JCAD research performed on 15628 patients with significant coronary stenosis, elevated serum level of CRP was clearly shown to be an independent predictor of cardiovascular events.
2. Jeppesen J, Hansen TW, Olsen MH, et al. C-reactive protein, insulin resistance and risk of cardiovascular disease: a population-based study. Eur J Cardiovasc Prev Rehabil 2008; 15:594-598.
3. Ridker PM, Danilson E, Fonsea FAH, et al. Rosuvastatin to prevent events in men and women with elevated C-reactive protein. N Eng J Med 2008; 359:2195-2207. In the JUPITER trial, it was shown in 17 802 healthy participants without hyperlipidemia, but with high serum CRP protein levels, that the statin rosuvastatin, significantly decreased the incidence of major CVD events such as myocardial infarction, stroke, or death from cardiovascular causes, in parallel to a reduction in LDL cholesterol levels by 50% and in high-sensitivity CRP levels by 37%.
4. Rosenblat M, Aviram M., Paraoxonases (PONs) role in the prevention of cardiovascular diseases. Biofactors 2009; 35:98-104.
5. Stephens JW, Bain SC, Humphries SE. Gene-environment interaction and oxidative stress in cardiovascular disease. Atherosclerosis 2008; 200:229-236.
6. Yokoyama H, Kawal K, Ohishi M, et al. Familial predisposition to cardiovas- cular risk and disease contributes to cardiovascular risk and disease interacting with other cardiovascular risk factors in diabetes: implication for common soil (JDDM 14). Atherosclerosis 2008; 201:332-338. In nondiabetic patients, metabolic syndrome was not associated with increased CVD, and it was the impaired fasting glucose that was a better predictor for future diabetes than metabolic syndrome.
7. Dagenais GR, St-Pierre A, Gilbert P, et al. Comparison of prognosis for men with type 2 diabetes mellitus and men with cardiovascular disease. Can Med Assoc J 2009; 180:40-47.
8. Rock W, Rosenblat M, Miller-Lotan R, et al. Consumption of won- derful variety pomegranate juice (PJ) and extract (POMxl) by diabetic patients increases paraoxonase 1 (PON 1) association with HDL and stimulates its catalytic activities. J Agric Food Chem 2008; 56:8704-8713. Pomegranate juice consumption by diabetic patients does not worsen their diabetic parameters, but rather increases PON1 association with HDL, stabilizes the enzyme, and increases its catalytic activities.